BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 20208565)

  • 1. Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.
    Cooper SJ; Zou H; Legrand SN; Marlow LA; von Roemeling CA; Radisky DC; Wu KJ; Hempel N; Margulis V; Tun HW; Blobe GC; Wood CG; Copland JA
    Oncogene; 2010 May; 29(20):2905-15. PubMed ID: 20208565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression.
    Copland JA; Luxon BA; Ajani L; Maity T; Campagnaro E; Guo H; LeGrand SN; Tamboli P; Wood CG
    Oncogene; 2003 Sep; 22(39):8053-62. PubMed ID: 12970754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of TGF-β signaling in clear cell renal cell carcinoma cells.
    Boström AK; Lindgren D; Johansson ME; Axelson H
    Biochem Biophys Res Commun; 2013 May; 435(1):126-33. PubMed ID: 23618868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGFBR3 co-downregulated with GATA3 is associated with methylation of the GATA3 gene in bladder urothelial carcinoma.
    Liu XL; Xue BX; Lei Z; Yang DR; Zhang QC; Shan YX; Zhang HT
    Anat Rec (Hoboken); 2013 Nov; 296(11):1717-23. PubMed ID: 24124001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased expression of the type III TGF-β receptor enhances metastasis and invasion in hepatocellullar carcinoma progression.
    Zhang S; Sun WY; Wu JJ; Gu YJ; Wei W
    Oncol Rep; 2016 Apr; 35(4):2373-81. PubMed ID: 26882862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased TGFBR3/betaglycan expression enhances the metastatic abilities of renal cell carcinoma cells through TGF-β-dependent and -independent mechanisms.
    Nishida J; Miyazono K; Ehata S
    Oncogene; 2018 Apr; 37(16):2197-2212. PubMed ID: 29391598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling.
    Lee JD; Hempel N; Lee NY; Blobe GC
    Carcinogenesis; 2010 Feb; 31(2):175-83. PubMed ID: 19955393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming growth factor-β promotes aggressiveness and invasion of clear cell renal cell carcinoma.
    Sitaram RT; Mallikarjuna P; Landström M; Ljungberg B
    Oncotarget; 2016 Jun; 7(24):35917-35931. PubMed ID: 27166254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta.
    Hempel N; How T; Cooper SJ; Green TR; Dong M; Copland JA; Wood CG; Blobe GC
    Carcinogenesis; 2008 May; 29(5):905-12. PubMed ID: 18299279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2.
    You HJ; How T; Blobe GC
    Carcinogenesis; 2009 Aug; 30(8):1281-7. PubMed ID: 19325136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tumor-promoting role for soluble TβRIII in glioblastoma.
    Burghardt I; Schroeder JJ; Weiss T; Gramatzki D; Weller M
    Mol Cell Biochem; 2021 Aug; 476(8):2963-2973. PubMed ID: 33772427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type III transforming growth factor-beta (TGF-beta) receptor mediates apoptosis in renal cell carcinoma independent of the canonical TGF-beta signaling pathway.
    Margulis V; Maity T; Zhang XY; Cooper SJ; Copland JA; Wood CG
    Clin Cancer Res; 2008 Sep; 14(18):5722-30. PubMed ID: 18794080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming growth factor-beta pathway in human renal cell carcinoma and surrounding normal-appearing renal parenchyma.
    Cardillo MR; Lazzereschi D; Gandini O; Di Silverio F; Colletta G
    Anal Quant Cytol Histol; 2001 Apr; 23(2):109-17. PubMed ID: 11332076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression.
    Gordon KJ; Dong M; Chislock EM; Fields TA; Blobe GC
    Carcinogenesis; 2008 Feb; 29(2):252-62. PubMed ID: 17999987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma.
    Fabrizio FP; Costantini M; Copetti M; la Torre A; Sparaneo A; Fontana A; Poeta L; Gallucci M; Sentinelli S; Graziano P; Parente P; Pompeo V; De Salvo L; Simone G; Papalia R; Picardo F; Balsamo T; Flammia GP; Trombetta D; Pantalone A; Kok K; Paranita F; Muscarella LA; Fazio VM
    Oncotarget; 2017 Feb; 8(7):11187-11198. PubMed ID: 28061437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth.
    Gatza CE; Holtzhausen A; Kirkbride KC; Morton A; Gatza ML; Datto MB; Blobe GC
    Neoplasia; 2011 Aug; 13(8):758-70. PubMed ID: 21847367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PLAGL1 (ZAC1/LOT1) Expression in Clear Cell Renal Cell Carcinoma: Correlations with Disease Progression and Unfavorable Prognosis.
    Godlewski J; Krazinski BE; Kowalczyk AE; Kiewisz J; Kiezun J; Kwiatkowski P; Sliwinska-Jewsiewicka A; Maslowski Z; Kmiec Z
    Anticancer Res; 2016 Feb; 36(2):617-24. PubMed ID: 26851016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma.
    Schrödter S; Braun M; Syring I; Klümper N; Deng M; Schmidt D; Perner S; Müller SC; Ellinger J
    Mol Cancer; 2016 Feb; 15():10. PubMed ID: 26831905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer.
    Yamamura S; Matsumura N; Mandai M; Huang Z; Oura T; Baba T; Hamanishi J; Yamaguchi K; Kang HS; Okamoto T; Abiko K; Mori S; Murphy SK; Konishi I
    Int J Cancer; 2012 Jan; 130(1):20-8. PubMed ID: 21503873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-Ski accelerates renal cancer progression by attenuating transforming growth factor β signaling.
    Taguchi L; Miyakuni K; Morishita Y; Morikawa T; Fukayama M; Miyazono K; Ehata S
    Cancer Sci; 2019 Jun; 110(6):2063-2074. PubMed ID: 30972853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.